Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

被引:171
作者
Lazar-Molnar, Eszter [1 ]
Yan, Qingrong [2 ]
Cao, Erhu [2 ]
Ramagopal, Udupi [3 ]
Nathenson, Stanley G. [1 ,2 ]
Almo, Steven C. [3 ,4 ]
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA
[3] Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA
[4] Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA
关键词
costimulation; coinhibition; inhibitory receptor; T cell activation;
D O I
10.1073/pnas.0804453105
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Programmed death-1 (PD-1) is a member of the CD28/B7 superfamily that delivers negative signals upon interaction with its two ligands, PD-L1 or PD-L2. The high-resolution crystal structure of the complex formed by the complete ectodomains of murine PD-1 and PD-L2 revealed a 1:1 receptor:ligand stoichiometry and displayed a binding interface and overall molecular organization distinct from that observed in the CTLA-4/B7 inhibitory complexes. Furthermore, our structure also provides insights into the association between PD-1 and PD-L1 and highlights differences in the interfaces formed by the two PD-1 ligands (PD-Ls) Mutagenesis studies confirmed the details of the proposed PD-1/PD-L binding interfaces and allowed for the design of a mutant PD-1 receptor with enhanced affinity. These studies define spatial and organizational constraints that control the localization and signaling of PD-1/PD-L complexes within the immunological synapse and provide a basis for manipulating the PD-1 pathways for immunotherapy.
引用
收藏
页码:10483 / 10488
页数:6
相关论文
共 28 条
[1]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[2]   Different cell surface oligomeric states of B7-1 and B7-2: Implications for signaling [J].
Bhatia, S ;
Edidin, M ;
Almo, SC ;
Nathenson, SG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (43) :15569-15574
[3]   Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses [J].
Butte, Manish J. ;
Keir, Mary E. ;
Phamduy, Theresa B. ;
Sharpe, Arlene H. ;
Freeman, Gordon J. .
IMMUNITY, 2007, 27 (01) :111-122
[4]   Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity [J].
Chen, LP .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (05) :336-347
[5]   Crystal structure of a soluble CD28-Fab complex [J].
Evans, EJ ;
Esnouf, RM ;
Manso-Sancho, R ;
Gilbert, RJC ;
James, JR ;
Yu, C ;
Fennelly, JA ;
Vowles, C ;
Hanke, T ;
Walse, B ;
Hünig, T ;
Sorensen, P ;
Stuart, DI ;
Davis, SJ .
NATURE IMMUNOLOGY, 2005, 6 (03) :271-279
[6]   Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].
Freeman, GJ ;
Long, AJ ;
Iwai, Y ;
Bourque, K ;
Chernova, T ;
Nishimura, H ;
Fitz, LJ ;
Malenkovich, N ;
Okazaki, T ;
Byrne, MC ;
Horton, HF ;
Fouser, L ;
Carter, L ;
Ling, V ;
Bowman, MR ;
Carreno, BM ;
Collins, M ;
Wood, CR ;
Honjo, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034
[7]   The B7 family revisited [J].
Greenwald, RJ ;
Freeman, GJ ;
Sharpe, AH .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :515-548
[8]   Structure and dimerization of a soluble form of B7-1 [J].
Ikemizu, S ;
Gilbert, RJC ;
Fennelly, JA ;
Collins, AV ;
Harlos, K ;
Jones, EY ;
Stuart, DI ;
Davis, SJ .
IMMUNITY, 2000, 12 (01) :51-60
[9]   Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-lg with potent immunosuppressive properties [J].
Larsen, CP ;
Pearson, TC ;
Adams, AB ;
Tso, P ;
Shirasugi, N ;
Strobert, E ;
Anderson, D ;
Cowan, S ;
Price, K ;
Naemura, J ;
Emswiler, J ;
Greene, JA ;
Turk, LA ;
Bajorath, J ;
Townsend, R ;
Hagerty, D ;
Linsley, PS ;
Peach, RJ .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (03) :443-453
[10]   PD-L2 is a second ligand for PD-I and inhibits T cell activation [J].
Latchman, Y ;
Wood, CR ;
Chernova, T ;
Chaudhary, D ;
Borde, M ;
Chernova, I ;
Iwai, Y ;
Long, AJ ;
Brown, JA ;
Nunes, R ;
Greenfield, EA ;
Bourque, K ;
Boussiotis, VA ;
Carter, LL ;
Carreno, BM ;
Malenkovich, N ;
Nishimura, H ;
Okazaki, T ;
Honjo, T ;
Sharpe, AH ;
Freeman, GJ .
NATURE IMMUNOLOGY, 2001, 2 (03) :261-268